Project Information

Bid Title

Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium

Issuing Agency

Location

District of Columbia

Published Date

Jun 18, 2026

Closing Date

Jul 2, 2026

Government Level

Federal

Status

Closed

Ref. #

RRPV-26-13-BundiVx

Original Source

Join to Access Full Details

Bid Inquiries

Join to Access Full Details

Bid Documents

Join to Access Full Details

Set Aside

No Set aside used

Project Description

Follow

Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium

Active

Contract Opportunity

Notice ID

RRPV-26-13-BundiVx

Related Notice

Department/Ind. Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub-tier

OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Office

BARDA - ASPR / DAAPPO / BARDA DCMA

Looking for contract opportunity help?

(opens in new window)

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information View Changes

• Contract Opportunity Type: Solicitation (Updated)
• Updated Published Date: Jun 18, 2026 08:17 am EDT
• Original Published Date: Jun 11, 2026 01:18 pm EDT
• Updated Date Offers Due: Jul 02, 2026 01:00 pm EDT
• Original Date Offers Due: Jun 26, 2026 03:00 pm EDT
• Inactive Policy: 15 days after date offers due
• Updated Inactive Date: Jul 17, 2026
• Original Inactive Date: Jul 11, 2026
• Initiative:
  • None

Classification

• Original Set Aside: No Set aside used
• Product Service Code: AN23 - HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; EXPERIMENTAL DEVELOPMENT
• NAICS Code:
  • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
• Place of Performance:
  Washington , DC 20024
  USA

Description

UPDATE: Question and Answers attached in documents. Date for submission revised to July 2, 2026.

The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows:

The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks.

Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10,000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical. The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100,000 doses of cGMP CTM.

The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development.

Please see the attachments for more information.

Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern.

Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/

Attachments/Links

Contact Information View Changes

Contracting Office Address

• O’NEILL HOUSE OFFICE BUILDING
• WASHINGTON , DC 20515
• USA

Primary Point of Contact

• Veronica Stroud
• veronica.stroud@hhs.gov
• Phone Number 2027313103

Secondary Point of Contact

• Jonathan Gonzalez, Contracting Officer
• Jonathan.Gonzalez@hhs.gov

History

• Jun 18, 2026 08:17 am EDTSolicitation (Updated)
• Jun 17, 2026 03:43 pm EDT Solicitation (Updated)
• Jun 17, 2026 03:41 pm EDT Solicitation (Updated)
• Jun 11, 2026 01:18 pm EDT Solicitation (Original)

Commodity Codes

• FSC AResearch and development

• NAICS 541714Research and Development in Biotechnology (except Nanobiotechnology)

Related bids

Jun 11, 2026	[Solicitation (Original)] Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium
Jun 17, 2026	[Solicitation (Updated)] Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium

* Disclaimer: Government BidHub provides information on bids, RFPs (Requests for Proposals), and RFQs (Requests for Qualifications) solely for convenience and informational purposes. This site is not an official public notice board. For official details, responses, or inquiries, please contact the relevant government agency directly.